163 related articles for article (PubMed ID: 32355783)
1. Prognostic significance of mutant-allele tumor heterogeneity in uterine corpus endometrial carcinoma.
Hou Y; Li T; Gan W; Lv S; Zeng Z; Yan Z; Wang W; Yang M
Ann Transl Med; 2020 Mar; 8(6):339. PubMed ID: 32355783
[TBL] [Abstract][Full Text] [Related]
2. Identification and Validation of Cuproptosis-Related Prognostic Signature and Associated Regulatory Axis in Uterine Corpus Endometrial Carcinoma.
Chen Y
Front Genet; 2022; 13():912037. PubMed ID: 35937995
[No Abstract] [Full Text] [Related]
3. Multiomics profile and prognostic gene signature of m6A regulators in uterine corpus endometrial carcinoma.
Wang Y; Ren F; Song Z; Wang X; Ma X
J Cancer; 2020; 11(21):6390-6401. PubMed ID: 33033522
[TBL] [Abstract][Full Text] [Related]
4. Identification of methylation-driven genes prognosis signature and immune microenvironment in uterus corpus endometrial cancer.
Liu J; Ji C; Wang Y; Zhang C; Zhu H
Cancer Cell Int; 2021 Jul; 21(1):365. PubMed ID: 34246261
[TBL] [Abstract][Full Text] [Related]
5. Gender-related prognostic value and genomic pattern of intra-tumor heterogeneity in colorectal cancer.
Zhang J; Yan S; Liu X; Gan L; Wu Z; Gong Y; Huang M; Zhang X; Guo W
Carcinogenesis; 2017 Aug; 38(8):837-846. PubMed ID: 28531253
[TBL] [Abstract][Full Text] [Related]
6. RPP40 is a prognostic biomarker and correlated with tumor microenvironment in uterine corpus endometrial carcinoma.
Tang J; Tian X; Min J; Hu M; Hong L
Front Oncol; 2022; 12():957472. PubMed ID: 36091104
[TBL] [Abstract][Full Text] [Related]
7. Clinical and molecular relevance of mutant-allele tumor heterogeneity in breast cancer.
Ma D; Jiang YZ; Liu XY; Liu YR; Shao ZM
Breast Cancer Res Treat; 2017 Feb; 162(1):39-48. PubMed ID: 28093659
[TBL] [Abstract][Full Text] [Related]
8. KDM4B, a potential prognostic biomarker revealed by large-scale public databases and clinical samples in uterine corpus endometrial carcinoma.
Zhang M; Liu Y; Hou S; Wang Y; Wang C; Yin Y; Chen X
Mol Omics; 2022 Jul; 18(6):506-519. PubMed ID: 35485290
[TBL] [Abstract][Full Text] [Related]
9. Integrated analysis of tumor mutation burden and immune infiltrates in endometrial cancer.
Zhou H; Chen L; Lei Y; Li T; Li H; Cheng X
Curr Probl Cancer; 2021 Apr; 45(2):100660. PubMed ID: 33012523
[TBL] [Abstract][Full Text] [Related]
10. Identification of an Immune-Related LncRNA Prognostic Signature in Uterine Corpus Endometrial Carcinoma Patients.
Sun XX; Wen HQ; Zhan BX; Yang P
Clin Lab; 2021 Nov; 67(11):. PubMed ID: 34758230
[TBL] [Abstract][Full Text] [Related]
11. The Expression of Pyroptosis-Related Gene May Influence the Occurrence, Development, and Prognosis of Uterine Corpus Endometrial Carcinoma.
Huang X; Li Y; Li J; Yang X; Xiao J; Xu F
Front Oncol; 2022; 12():885114. PubMed ID: 35574367
[TBL] [Abstract][Full Text] [Related]
12. TPD52 as a Potential Prognostic Biomarker and its Correlation with Immune Infiltrates in Uterine Corpus Endometrial Carcinoma: Bioinformatic Analysis and Experimental Verification.
Miao L; Chen B; Jing L; Zeng T; Chen Y
Recent Pat Anticancer Drug Discov; 2024 Jan; ():. PubMed ID: 38305309
[TBL] [Abstract][Full Text] [Related]
13. LYL1 gene amplification predicts poor survival of patients with uterine corpus endometrial carcinoma: analysis of the Cancer genome atlas data.
Kim SI; Lee JW; Lee N; Lee M; Kim HS; Chung HH; Kim JW; Park NH; Song YS; Seo JS
BMC Cancer; 2018 May; 18(1):494. PubMed ID: 29716549
[TBL] [Abstract][Full Text] [Related]
14. Intra-tumor genetic heterogeneity and mortality in head and neck cancer: analysis of data from the Cancer Genome Atlas.
Mroz EA; Tward AD; Hammon RJ; Ren Y; Rocco JW
PLoS Med; 2015 Feb; 12(2):e1001786. PubMed ID: 25668320
[TBL] [Abstract][Full Text] [Related]
15. The landscape and prognostic value of immune characteristics in uterine corpus endometrial cancer.
Liu W; Sun L; Zhang J; Song W; Li M; Wang H
Biosci Rep; 2021 Apr; 41(4):. PubMed ID: 33782686
[TBL] [Abstract][Full Text] [Related]
16. Inflammation-Related LncRNAs Signature for Prognosis and Immune Response Evaluation in Uterine Corpus Endometrial Carcinoma.
Gu H; Song J; Chen Y; Wang Y; Tan X; Zhao H
Front Oncol; 2022; 12():923641. PubMed ID: 35719911
[TBL] [Abstract][Full Text] [Related]
17. Mammaglobin B may be a prognostic biomarker of uterine corpus endometrial cancer.
Li J; Xu W; Zhu Y
Oncol Lett; 2020 Nov; 20(5):255. PubMed ID: 32994818
[TBL] [Abstract][Full Text] [Related]
18. Machine learning combined with single-cell analysis reveals predictive capacity and immunotherapy response of T cell exhaustion-associated lncRNAs in uterine corpus endometrial carcinoma.
Jiang F; Tao Z; Zhang Y; Xie X; Bao Y; Hu Y; Ding J; Wu C
Cell Signal; 2024 May; 117():111077. PubMed ID: 38311301
[TBL] [Abstract][Full Text] [Related]
19. Development of an Oxidative Phosphorylation-Related and Immune Microenvironment Prognostic Signature in Uterine Corpus Endometrial Carcinoma.
Liu J; Chen T; Yang M; Zhong Z; Ni S; Yang S; Shao F; Cai L; Bai J; Yu H
Front Cell Dev Biol; 2021; 9():753004. PubMed ID: 34901000
[No Abstract] [Full Text] [Related]
20. Tumor mutation burden in connection with immune-related survival in uterine corpus endometrial carcinoma.
Zhao L; Fu X; Han X; Yu Y; Ye Y; Gao J
Cancer Cell Int; 2021 Jan; 21(1):80. PubMed ID: 33509222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]